The user saw hair improvement with minoxidil, finasteride, and a red light cap, noting better results after adding finasteride and stressing routine consistency.
PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.
Scalp tension from the occipitalis muscle is theorized to contribute to hair loss, but most believe DHT and genetics are the main causes. Treatments like finasteride and minoxidil are considered more effective than addressing scalp tension.
PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.
A user experienced significant hair regrowth using finasteride 1 mg daily for two years and gradually introduced dutasteride 0.5 mg daily over four months. They reported no side effects and plan to switch fully to dutasteride due to its cost-effectiveness and potential effectiveness.
A 31-year-old woman is using Dutasteride (0.5mg daily) and supplements like a multivitamin, Herbadal, pumpkin seed oil, and vitamin D for genetic hair loss, noticing thicker hair but no new growth after one month. She is considering adding minoxidil and is aware of Dutasteride's risks, especially regarding pregnancy.
PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.
Increased Malassezia and Cutibacterium in the scalp microbiome are linked to higher sebum production and inflammation in androgenetic alopecia (AGA). Treatments include ciclopirox shampoo, benzoyl peroxide shampoo, clobetasol propionate, calcipotriol, minoxidil, finasteride, and dutasteride.
AI advancements, like AlphaFold, are speeding up drug discovery for hair loss, promising more effective treatments. Current options like minoxidil and finasteride have limitations, but new developments could improve solutions in 5-10 years.
DUPA and retrograde alopecia may not be solely DHT-based, and a biopsy is crucial for accurate diagnosis and treatment. Treatments mentioned include dutasteride, oral minoxidil, pioglitazone, clobetasol, calcipotriol, ketoconazole, and doxycycline, depending on the specific condition.
Hair loss treatments like finasteride, minoxidil, and hair transplants are more accessible and effective now. Concerns about side effects and skepticism about new treatments like hair cloning and GT20029 remain.
Many are unaware of effective male pattern baldness treatments like finasteride and minoxidil, often opting for ineffective remedies. Educating others on proven treatments and potential side effects is crucial.
The user is happy with hair regrowth after 60 days using topical minoxidil 5% and finasteride 0.1%, along with a dermaroller. They report no significant side effects and plan to continue treatment for a year.
Dutasteride has been used for 20 years with some hair thickness improvement but no dramatic regrowth. The user also experimented with minoxidil, tretinoin, and peptides like BPC 157 for potential benefits in hair density and quality.
The user shared their experience with Finasteride and Dutasteride for hair loss. They initially had success with Finasteride but switched to Dutasteride after experiencing shedding, which continued, and are now considering a hair transplant.
Peptides like TB500, KPV, GHK-CU, and BPC-157 are overhyped for hair growth with limited proven effectiveness in humans. Combining peptides with delivery methods like iontophoresis and sonophoresis shows promise, but many claims remain unproven.
A user diagnosed with AGA is seeking advice on hair loss treatments, comparing topical Minoxidil, Spironolactone, and Finasteride to oral medications and natural methods like dermastamping, PRP, and LED light. They are concerned about side effects and effectiveness, especially given their existing fatigue.
The conversation discusses HMI 115, a new hair loss treatment with promising results, showing a significant increase in hair density after two months. Some users are skeptical, while others are hopeful for its release and potential affordability.
The conversation discusses the use of hair systems as a solution for hair loss. Users share their experiences, highlighting the natural look, confidence boost, and maintenance requirements of hair systems, while also addressing concerns about cost, stigma, and potential drawbacks.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
The potential effectiveness of homemade topical spironolactone in treating hair loss, with studies suggesting it is more effective than finasteride and even minoxidil when used as monotherapy. The conversation also mentions that other anti-androgens are being developed which may soon hit the market.
Scalp tension potentially affecting hair loss, and potential treatments for male pattern baldness such as Minoxidil, Finasteride and RU58841. Evidence from a study was discussed which suggests that the cause of MPB lies within the follicle itself and is not dependent on its surrounding environment.
Hair regrowth treatments for cis-males include Minoxidil, Finasteride, and RU58841. Estrogen and testosterone blockers can help restore hair loss but may not suit everyone.
Evidence-based treatments for androgenic alopecia, such as minoxidil, finasteride, low-level laser light therapy, dutasteride, platelet-rich plasma, and topical ketoconazole. It discusses the efficacy, safety, and mechanism of action of these treatments, as well as future developments in understanding this polygenic condition.
Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.
Finasteride may affect neurosteroids, impacting mood and sexual function, with varied user experiences. Some report side effects like depression and sexual dysfunction, while others find it effective for hair retention or prefer alternatives like Dutasteride or topical treatments.
Oral minoxidil is effective for hair loss but can cause cardiovascular side effects, such as pericardial effusion, especially in those with genetic predispositions. Starting with low doses and monitoring cardiovascular health are advised to reduce risks.
Finasteride and dutasteride can improve skin texture and reduce acne by lowering DHT but do not reverse aging. They may enhance skin and hair health for some, but can also cause side effects like dry skin and sexual dysfunction.